AstraZeneca PLC (AZN)

AZN (NYSE:Drugs) EQUITY
$32.97
neg -0.26
-0.78%
Today's Range: 32.79 - 33.45 | AZN Avg Daily Volume: 6,224,000
Last Update: 08/26/16 - 1:26 PM EDT
Volume: 3,641,387
YTD Performance: -2.12%
Open: $33.15
Previous Close: $33.23
52 Week Range: $26.97 - $35.04
Oustanding Shares: 2,530,000,000
Market Cap: 84,755,000,000
6-Month Chart
TheStreet Ratings Grade for AZN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 1 1 1 1
Moderate Buy 0 0 0 0
Hold 3 3 3 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.50 2.50 2.50 2.60
Latest Dividend: 0.44
Latest Dividend Yield: 4.09%
Dividend Ex-Date: 08/10/16
Price Earnings Ratio: 15.02
Price Earnings Comparisons:
AZN Sector Avg. S&P 500
15.02 38.30 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
10.84% 9.74% 31.16%
GROWTH 12 Mo 3 Yr CAGR
Revenue -5.30 -0.10 -0.04
Net Income 128.80 -0.60 -0.23
EPS 127.60 -0.60 -0.23
Earnings for AZN:
EBITDA 5.47B
Revenue 24.71B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $0.58 $0.58 $2.07 $1.96
Number of Analysts 2 1 3 3
High Estimate $0.61 $0.58 $2.08 $2.03
Low Estimate $0.55 $0.58 $2.05 $1.81
Prior Year $1.03 $0.94 $4.26 $2.07
Growth Rate (Year over Year) -43.69% -38.30% -51.49% -5.32%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.
There's a price to pay for low expectations.
Barring a strong rally over $31 that has follow-through, we look for AZN to slowly erode.

Bret Jensen Reporting for Duty Real Money Pro($)

Good morning! Bret Jensen here!
Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.
Small biotech has plenty of cash and a very valuable drug.
Small biotech has plenty of cash and a very valuable drug.
CEO Read says the Viagra maker retains the means to pursue 'attractive business development' opportunities as he tears up the six-month-old deal with the maker of Botox.
They are oversold and lately been on the move.
Drug maker Relypsa is poised for a huge upside, despite the current market sentiment.

Columnist Conversations

FIBOCALL: The SPX-cash after Ms. Yellen speaks. The "markets" actually moved today after the FED spoke. Fir...
Finally going to hear the latest views of Yellen today and the market and investor have largely been on hold b...
The BLS revised second quarter 20-16 GDP lower by 0.1% to 1.1%. This should provide adequate cover for the Fe...
We have followed all areas of the Healthcare industry for decades. And while there are likely many causes for ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.